low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. Patient enrollment may see modest impacts during severe recessions affecting healthcare access, but psychiatric conditions remain prevalent across economic cycles. The 484% one-year return reflects biotech-specific catalysts rather than macro trends.

Rising rates create moderate headwinds through two channels: (1) higher discount rates compress NPV of distant future cash flows (first revenue likely 2027+), making pre-revenue biotech less attractive versus current income alternatives, and (2) increased cost of capital for future financing rounds. However, clinical success can override rate impacts - the stock's 465% six-month gain occurred despite Fed tightening. Rate sensitivity manifests more in sector rotation than fundamental business impact.

growth/momentum - Attracts high-risk biotech specialists and momentum traders betting on binary clinical catalysts. The 485% one-year return and 55% three-month gain reflect speculative positioning ahead of data readouts rather than fundamental cash flow analysis. Institutional ownership likely concentrated among healthcare-focused funds with expertise evaluating clinical trial design and CNS drug development. Not suitable for income or value investors given zero revenue, negative margins, and valuation entirely dependent on probability-weighted future scenarios.